Additionally, based on the beneficial combination therapy of UCN-01 and irinotecan in p53-loss triple negative breast cancer (TNBC) in vivo with xenograft mice models [91], Ma et al. further executed a phase II clinical trial of combination therapy of UCN-01 and irinotecan in 25 patients with metastatic TNBC and found that effective UCN-01 could enhance irinotecan-induced apoptosis in TP53-mutant BCs (69% of tumors were basal-like BCs, BLBCs); they also illustrated the molecular heterogeneity of TNBC and correlated the relevance of TP53-mutant TNBC to a pretty poor survival. This evidence concerns the gene TP53 and triple-negative breast carcinoma.